新华制药(000756) - 2019 Q1 - 季度财报

Financial Performance - Revenue for the first quarter reached ¥1,617,765,684.10, an increase of 14.14% compared to ¥1,417,348,459.35 in the same period last year[7] - Net profit attributable to shareholders was ¥75,444,841.65, reflecting an 11.62% increase from ¥67,593,570.18 year-on-year[7] - Net profit excluding non-recurring gains and losses was ¥72,681,010.68, up 11.42% from ¥65,231,667.77 in the previous year[7] - Operating profit for Q1 2019 grew by 20.32% to RMB 100,371,244.74, with net profit attributable to shareholders increasing by 11.62% to RMB 75,444,841.65[21] - Net profit for the current period was ¥81,850,161.21, representing a 17.86% increase from ¥69,847,828.32 in the previous period[49] - The net profit attributable to the parent company's shareholders was ¥75,444,841.65, compared to ¥67,593,570.18 in the previous period, reflecting an increase of 11.00%[49] Cash Flow - Operating cash flow for the period was ¥56,302,679.51, a significant improvement from a negative cash flow of ¥4,063,722.33 in the same period last year, marking a 1,485.50% increase[7] - Cash flow from operating activities generated a net cash inflow of ¥56,302,679.51, compared to a net outflow of ¥4,063,722.33 in the prior period[57] - Cash outflows from investing activities totaled ¥143,181,825.90, compared to ¥67,235,110.46 in the prior period, indicating increased investment activity[58] - Cash flow from financing activities resulted in a net outflow of ¥50,826,691.79, a decrease from a net inflow of ¥40,479,555.48 in the previous period[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,040,069,275.99, a 2.09% increase from ¥5,916,156,319.63 at the end of the previous year[7] - Total liabilities increased to ¥3,133,316,926.87 from ¥3,119,603,287.55, reflecting a growth of approximately 0.7%[39] - Current liabilities decreased from ¥2,360,044,632.17 to ¥2,351,982,499.16, a reduction of about 0.3%[39] - Non-current liabilities rose to ¥781,334,427.71 from ¥759,558,655.38, indicating an increase of approximately 2.3%[39] - Owner's equity increased to ¥2,906,752,349.12 from ¥2,796,553,032.08, representing a growth of about 3.9%[39] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,721[10] - The largest shareholder, Shandong Xinhua Pharmaceutical Group Co., Ltd., held 32.94% of the shares, totaling 204,864,092 shares[10] Expenses - Sales expenses for Q1 2019 increased by 35.35% to RMB 259,986,101.12, driven by intensified market development efforts[19] - R&D expenses rose by 33.43% to RMB 57,253,929.71, reflecting increased investment in research and development[19] - Research and development expenses increased to ¥57,253,929.71, a rise of 33.47% from ¥42,910,383.28 in the previous period[47] - Sales expenses rose to ¥259,986,101.12, an increase of 35.38% compared to ¥192,083,579.25 in the previous period[47] Comprehensive Income - Other comprehensive income after tax for the current period was ¥26,257,980.83, compared to a loss of ¥33,207,681.02 in the previous period[49] - The total comprehensive income for the current period was ¥108,108,142.04, significantly higher than ¥36,640,147.30 in the previous period[50] - Total comprehensive income amounted to ¥106,095,348.85, a significant increase from ¥37,362,777.84 in the previous period[54] Adjustments and Standards - The company adjusted its balance sheet on January 1, 2019, increasing the right-of-use assets by CNY 1,516,217.37 due to the new leasing standards[75] - The company also increased current liabilities due within one year by CNY 484,044.54 and lease liabilities by CNY 1,032,172.83 as part of the adjustments[75] - The total assets increased by CNY 1,516,217.37 following the implementation of the new leasing standards[75] - The company did not apply retrospective adjustments for prior comparative data under the new financial instrument standards and leasing standards[76] Audit Status - The first quarter report was not audited[77]